Highlights from ASCO GU 2018
ASCO GU 2018: Outcomes and Patterns of Disease Progression in Metastatic Renal Cell Carcinoma Patients Treated with Nivolumab
Background:
Nivolumab (nivo) has been approved for the treatment of refractory metastatic renal cell carcinoma (mRCC). Data regarding the characteristics and outcomes of patients who progress on nivo are lacking.
ASCO GU 2018: The Impact of Facility Case Volume on Overall Survival in Patients with Metastatic Renal Cell Carcinoma in The Targeted Therapy Era
ASCO GU 2018: Impact of Intravenous Acetaminophen on Outcomes following Radical Nephrectomy
Background:
Intravenous acetaminophen (IVA) was approved for use in the US for moderate to severe pain in 2010. The role of postoperative IVA following radical nephrectomy (RN) is of particular interest given the potential nephrotoxic and bleeding risks associated with other non-opioid alternatives, such as parenteral non-steroidal anti-inflammatory drugs. However, given the relatively high cost of IVA versus other pain medications, the benefit of IVA in the postoperative period is unclear. Therefore, the authors sought to determine if the use of postoperative IVA is associated with improved outcomes following RN.
ASCO GU 2018: Defining Individual Recurrence Risk Following Surgery for High Risk Non-Metastatic Renal Cell Carcinoma
ASCO GU 2018: Utilization and Survival Implications of a Delayed Approach to Targeted Therapy for Metastatic Renal Cell Carcinoma: A Nationwide Cancer Registry Study
ASCO GU 2018: Imaging Modalities Used for Follow-Up of Localized Renal Cell Carcinoma and Subsequent Effect on Overall Survival after Recurrence: RECUR-Database Analysis
Background:
Cross-sectional imaging (CSI) has emerged as the preferred imaging modality for staging and follow-up (FU). Moreover, the 2017 EAU renal cell carcinoma (RCC) guidelines discourage the use of Chest X-Ray (CXR). In an international database (RECUR) data were collected to compare imaging modalities in contemporary FU, and to explore if more frequent use of CSI translates into improved overall survival (OS) after recurrence.